ASND•benzinga•
Oppenheimer Maintains Outperform on Ascendis Pharma, Lowers Price Target to $180
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga